hMAO-B/MB-COMT-IN-2 是一种双重的MAO-B/MB-COMT抑制剂 (IC50s: hMAO-B 为 2.5 μM，MB-COMT 为 3.84 μM)。hMAO-B/MB-COMT-IN-2 可保护细胞免受氧化损伤。hMAO-B/MB-COMT-IN-2 可用于帕金森病 (PD) 等神经退行性疾病的研究。

hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor ( IC 50 s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) [1].

hMAO-B/MB-COMT-IN-2 (compound 8, 50 μM, 24 h) decreases in resazurin reduction in differentiated SH-SY5Y cells [1]. hMAO-B/MB-COMT-IN-2 (50 μM, 24 h) displays lysosomal toxicity by producing ROS in differentiated SH-SY5Y cells [1]. hMAO-B/MB-COMT-IN-2 (10 μM, 30 min) displays remarkable cytoprotective effects against t-BHP in differentiated SH-SY5Y cells [1]. hMAO-B/MB-COMT-IN-2 is predicted to cross the blood-brain barrier (BBB) by passive diffusion, determined by the parallel artificial membrane permeability assay (PAMPA)-BBB kit [1]. hMAO-B/MB-COMT-IN-2 (30-50 μM, 24 h) has good safety profile in SK-N-SH cells [1].

C17H18N2O3

298.34

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years